Profile
Erle T.
Mast is the founder of Clovis Oncology, Inc. (founded in 2009), where he held the title of Chief Financial Officer, Secretary & Executive VP from 2012 to 2016.
He also held former positions as an Independent Director at Somaxon Pharmaceuticals, Inc. (2008-2013), Director at Verus Pharmaceuticals, Inc. (2007-2009), Independent Director at Zogenix, Inc. (2008-2022), Independent Director at Receptos LLC (2014-2015), Independent Director at Sienna Biopharmaceuticals, Inc. (2017-2018), Vice President-Finance at Dura Pharmaceuticals, Inc. (1997-2000), Chief Financial Officer & Executive Vice President at Pharmion Corp.
(2002-2008), and CFO-Global Biopharmaceuticals Business Unit at Elan Pharma International Ltd.
(2000-2002).
Mr. Mast's education history includes an undergraduate degree from California State University-Bakersfield.
Former positions of Erle T. Mast
| Companies | Position | End |
|---|---|---|
| ZOGENIX, INC. | Director/Board Member | 2022-03-06 |
| SIENNA BIOPHARMACEUTICALS, INC. | Director/Board Member | 2018-08-01 |
| CLOVIS ONCOLOGY, INC. | Founder | 2016-03-30 |
| RECEPTOS INC | Director/Board Member | 2015-08-26 |
Somaxon Pharmaceuticals, Inc.
 Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | Director/Board Member | 2012-12-31 |
Training of Erle T. Mast
| California State University-Bakersfield | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SIENNA BIOPHARMACEUTICALS, INC. | Health Technology |
| Private companies | 9 |
|---|---|
Dura Pharmaceuticals, Inc.
 Dura Pharmaceuticals, Inc. BiotechnologyHealth Technology Dura Pharmaceuticals, Inc. markets and sells prescription products that treat infectious and respiratory diseases. Dura focuses on products and transactions that leverage its sales and marketing organization. Dura also intends, through the use of collaborative relationships, to develop the Spiros® motorized blisterdisk and Spiros® S2 pulmonary drug delivery systems for the local and systemic delivery of a wide range of medications. It is located in San Diego, CA. | Health Technology |
Pharmion Corp.
 Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Somaxon Pharmaceuticals, Inc.
Somaxon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company focuses on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical conditions where there is an unmet medical need and high-level of patient dissatisfaction, currently in the central nervous system therapeutic area. Its product, Silenor, is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. Somaxon Pharmaceuticals was founded in August 2003 and is headquartered in Solana Beach, CA. | Health Technology |
Verus Pharmaceuticals, Inc.
 Verus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verus Pharmaceuticals, Inc. was provided pediatric-oriented pharmaceutical products. The company was founded by David A. Socks, James Carroll Blair, Robert W. Keith, Cam L. Garner and David F. Hale in 2002 and was headquartered in San Diego, CA. | Health Technology |
Elan Pharma International Ltd.
 Elan Pharma International Ltd. Pharmaceuticals: MajorHealth Technology Part of Perrigo Co. Plc, Elan Pharma International Ltd. develops, manufactures and distributes pharmaceutical products. The private company is based in South San Francisco, CA. | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Receptos LLC
 Receptos LLC Pharmaceuticals: MajorHealth Technology Receptos LLC engages in the provision of developing and commercializing of therapeutic candidates for the treatment of immune and inflammatory diseases. It offers Ozanimod for relapsing multiple sclerosis, Ozanimod for inflammatory bowel disease and RPC4046 for eosinophilic esophagitis. The company was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens on September 26, 2008 and is headquartered in San Diego, CA. | Health Technology |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Stock Market
- Insiders
- Erle T. Mast
